Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Abstract
CDK9 inhibitors may treat KRAS-mutant cancers by inducing MYC protein degradation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 16, 2019
- Source ID
- 10.1126/scisignal.aav7259
Entities
People
- Adrienne D Cox
- Angelina V. Vaseva
- Channing Der
- Daowei Huang
- Devon R Blake
- Gabrielle C Whiten
- Jacob E. Larson
- Kenneth H Pearce
- Laura E Herring
- Lee M. Graves
- Mckenzie P. Kline
- Michael J. Emanuele
- Richard G Hodge
- Stephen V Frye
- Thomas S K Gilbert
- Vikas Tyagi
- Xiaodong Wang
Organizations
- American Cancer Society
- Debbie's Dream Foundation
- Lustgarten Foundation for Pancreatic Cancer Research
- National Cancer Institute
- Pancreatic Cancer Action Network
- United States Department of Defense
- University of North Carolina at Chapel Hill